-
XW04306 Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04308 Introduction of Spesolimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 8
-
XW04326 Introduction of Nerinitide into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04336 Introduction of Durvalumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW0433A Introduction of Bentracimab, Ticagrelor Reversal Agent into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW0434A Introduction of Cefepime-taniborbactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW04357 Introduction of Narsoplimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04358 Introduction of Mosunetuzumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 8
-
XW0435A Introduction of Ceftobiprole Medocaril Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW04366 Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04367 Introduction of Terlipressin into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
XW04372 Introduction of Inactivated Coagulation Factor Xa into Central Vein, Percutaneous Approach, New Technology Group 2
-
XW04377 Introduction of Trilaciclib into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
-
XW04387 Introduction of Lurbinectedin into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW04388 Introduction of Treosulfan into Central Vein, Percutaneous Approach, New Technology Group 8
-
XW0438A Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW04396 Introduction of Ceftolozane/Tazobactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW04398 Introduction of Inebilizumab-cdon into Central Vein, Percutaneous Approach, New Technology Group 8
-
XW0439A Introduction of Odronextamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW043A6 Introduction of Cefiderocol Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043B3 Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043B6 Introduction of Omadacycline Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043B7 Introduction of Amivantamab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW043C6 Introduction of Eculizumab into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043CA Introduction of Zanidatamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW043D6 Introduction of Atezolizumab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043E5 Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043E6 Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043F3 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 3
-
XW043F5 Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043F6 Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
-
XW043G5 Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043G6 Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043H5 Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043H6 Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043K9 Introduction of Sulbactam-Durlobactam into Central Vein, Percutaneous Approach, New Technology Group 9
-
XW043L6 Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6
-
XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
-
XW043P9 Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
-
XW043Q5 Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043Q9 Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
-
XW043R9 Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
-
XW043S5 Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
-
XW043W5 Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5